Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy

Biomed Pharmacother. 2023 Apr:160:114382. doi: 10.1016/j.biopha.2023.114382. Epub 2023 Feb 9.

Abstract

Salvianolic acid A (SAA) is a traditional Chinese medicine that has a good therapeutic effect on cardiovascular disease. However, the underlying mechanisms by which SAA improves mitochondrial respiration and cardiac function in diabetic cardiomyopathy (DCM) remain unknown. This study aims to elucidate whether SAA had any cardiovascular protection on the pathophysiology of DCM and explored the potential mechanisms. Diabetes was induced in rats by 30 mg/kg of streptozotocin (STZ) treatment. After a week of stability, 5 mg/kg isoprenaline (ISO) was injected into the rats subcutaneously. 3 mg/kg SAA was orally administered for six weeks and 150 mg/kg Metformin was selected as a positive group. At the end of this period, cardiac function was assessed by ultrasound, electrocardiogram, and relevant cardiac injury biomarkers testing. Treatment with SAA improved cardiac function, glucose, and lipid levels, mitochondrial respiration, and suppressed myocardial inflammation and apoptosis. Furthermore, SAA treatment inhibits the apoptosis pathway through CRYAB in diabetic cardiomyopathy rats. As a result, this study not only provides new insights into the mechanism of SAA against DCM but also provides new therapeutic ideas for the discovery of anti-DCM compounds in the clinic.

Keywords: Apoptosis; CRYAB; Diabetic cardiomyopathy; Mitochondrial; Salvianolic acid A.

MeSH terms

  • Animals
  • Apoptosis
  • Diabetes Mellitus*
  • Diabetic Cardiomyopathies* / metabolism
  • Heart
  • Rats
  • Rats, Sprague-Dawley
  • Respiration

Substances

  • salvianolic acid A
  • cryaB protein, rat